文献速递主动脉外科

肾病患者的胸主动脉腔内修复术住院与再入院死亡率及费用的全国研究

National Study of Index and Readmission Mortality and Costs for Thoracic Endovascular Aortic Repair in Patients With Renal Disease.
PubMed 文献 · Ann Thorac Surg · 2019-07-20

该研究基于2010至2015年全国再入院数据库,分析不同肾功能分级的胸主动脉腔内修复术(TEVAR)患者结局。结果显示,终末期肾病(ESRD)患者死亡率、再入院率、住院时长和费用均显著高于无慢性肾病(NCKD)患者,而CKD1-3无显著差异。

要点

  • ESRD患者TEVAR后死亡率、再入院率、住院时长和费用显著高于NCKD患者。
  • CKD4-5和ESRD患者早期再入院率显著高于NCKD,CKD1-3无显著差异。
  • 再入院主要诊断以心血管、感染和血管并发症为主,各组间无显著差异。

核心结论

  • 仅ESRD患者TEVAR后死亡几率、再入院、住院时长和费用显著高于NCKD队列。

研究设计与样本

  • 回顾性队列研究,纳入2010至2015年全国再入院数据库中所有接受TEVAR的患者,按肾功能分为NCKD、CKD1-3、CKD4-5和ESRD四组。

主要发现

  • 估计121046例患者接受TEVAR,其中 elective 26653例(22.1%)。
  • ESRD占 elective TEVAR 的2.7%,占非 elective TEVAR 的5.4%。
  • ESRD患者住院费用显著高于NCKD组,差值为7456美元(95%CI:2629-12283美元)。
  • 再入院主要诊断为心血管、感染和血管并发症,NCKD与CKD4-5/ESRD组间无显著差异。

临床怎么用

  • 对ESRD患者行TEVAR应充分评估死亡、再入院、住院时长和费用风险。
  • CKD1-3患者TEVAR后早期再入院风险与NCKD无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the current era of value-based health care delivery, an understanding of patient populations at greatest risk for mortality, complications, and readmissions after thoracic endovascular aortic repair (TEVAR) is warranted. Thus, the present study aimed to evaluate outcomes after TEVAR for patients with varying degrees of renal dysfunction. METHODS: All patients who underwent TEVAR from 2010 to 2015 in the Nationwide Readmissions Database were identified. These patients were further stratified into four groups: no chronic kidney disease (NCKD), chronic kidney disease (CKD) stages 1 to 3 (CKD1-3), CKD 4 to 5 (CKD4-5), and end-stage renal disease (ESRD) requiring dialysis. Multivariable regression analysis was used to study index mortality, early (30 days) and intermediate (31-90 days) readmissions, costs, and length of stay. Kaplan-Meier analyses were performed to compare readmission performance among all four groups. RESULTS: An estimated 121,046 patients underwent TEVAR with 26,653 (22.1%) being elective. Patients with ESRD comprised 2.7% of elective and 5.4% of nonelective TEVAR operations. Patients with CKD4-5 (17.8%; P = .01) and with ESRD (21.1%; P < .001), but not with CKD1-3 (14.1%; P = .12), had remarkably higher early readmission rate than the NCKD cohort (9.2%). Patients with ESRD had remarkably higher hospitalization costs than the NCKD group ($7456; 95% confidence interval, $2629-$12,283). Cardiovascular, infectious, and vascular complications were the most prevalent diagnoses on readmission, with no remarkable difference among the NCKD and CKD4-5/ESRD groups. CONCLUSIONS: Nearly 10% of all patients with TEVAR have evidence of chronic kidney disease of varying severity. Only patients with ESRD are at risk of substantially higher odds of mortality, readmissions, index length of stay, and costs compared with the non-CKD cohort.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Sanaiha Y, Kavianpour B, Downey P, et al. National Study of Index and Readmission Mortality and Costs for Thoracic Endovascular Aortic Repair in Patients With Renal Disease. Ann Thorac Surg. 2019. PMID: 31336063. doi:10.1016/j.athoracsur.2019.05.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。